Intranasal Delivery of Engineered Extracellular Vesicles for Alzheimer's Disease Treatment
Author Information
Author(s): Peng Dong, Liu Tingting, Lu Huahui, Zhang Lei, Chen Hongxia, Huang Yadong, Hu Bo, Zhang Qihao
Primary Institution: Jinan University, Guangzhou, China
Hypothesis
Can engineered extracellular vesicles loaded with miR-206-3p antagomir improve Alzheimer's disease phenotypes when delivered intranasally?
Conclusion
The study found that intranasal administration of MSC-EVs-anta significantly improved cognitive deficits and reduced Aβ deposition in Alzheimer's disease mice.
Supporting Evidence
- MSC-EVs-anta improved learning and memory deficits in AD mice.
- Intranasal delivery of MSC-EVs-anta significantly reduced Aβ deposition.
- MSC-EVs-anta upregulated BDNF levels in the brains of AD mice.
- Transcriptome and proteomic analyses showed enrichment in neurogenesis and synapse pathways.
- MSC-EVs-anta promoted neurite outgrowth in vitro.
Takeaway
Scientists created tiny bubbles that carry medicine to help fix the brains of mice with Alzheimer's, and it worked really well when given through the nose.
Methodology
The study used engineered extracellular vesicles derived from mesenchymal stem cells loaded with miR-206-3p antagomir, delivered intranasally to AD mice, followed by various assessments including behavioral tests and molecular analyses.
Potential Biases
Potential bias in animal model selection and the interpretation of results may exist.
Limitations
The study was conducted in mice, and the long-term effects and safety in humans remain to be established.
Participant Demographics
8-week-old male C57BL/6J mice were used in the study.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website